The Filing Desk

Heron Therapeutics

HRTX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

HRTX · Last close · November 19, 2026
$0.26
Value Heron Therapeutics yourself

Heron Therapeutics' revenue rose 7.4% to $155 million in fiscal 2025. Its operating margin was −1.6%, up from −8.0% a year earlier. Free cash flow was −$28 million. The diluted share count rose 9.3%.

HERON THERAPEUTICS, INC. /DE/ Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-073515 Updated
Revenue
$155M
7.4%
Operating margin
−1.6%
6.4 pts
Net income
−$20M
 
Free cash flow
−$28M
 
Return on capital
−7.0%
12.8 pts
Market cap
$50M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Heron Therapeutics does

Heron Therapeutics sells four prescription drugs in the United States, used in hospitals and clinics around surgery and cancer treatment. Two are for surgery patients. ZYNRELEF combines a numbing drug and an anti-inflammatory and is applied during an operation to ease pain for up to 72 hours afterward, with the aim of reducing the need for opioids. APONVIE is an injection that prevents nausea and vomiting after surgery.

The other two are for cancer patients. CINVANTI, given by IV, and SUSTOL, an extended-release injection, help prevent the nausea and vomiting that chemotherapy can cause. Heron earns its money from sales of these products, and competes with other pain and anti-nausea drugs, including cheaper generics. How much hospitals are paid for using its drugs matters to sales: since April 2025, ZYNRELEF has qualified for separate Medicare payment under a federal law meant to encourage pain treatments other than opioids.

The company relies on outside suppliers and contract manufacturers to make its products, some of whose parts come from a single vendor. At the end of 2025 it had 128 full-time employees, most of them in sales and marketing.

Its biggest risks, as it describes them

  • Failing to keep strong enough sales and marketing to sell its products.
  • Pressure on the prices it can charge, and on how much government and insurers pay for its drugs.
  • Its dependence on outside manufacturers and, for some parts, on a single vendor.
  • Competition from other pain and anti-nausea drugs, including lower-cost generics.
  • Demand for its products is hard to predict, and it may have to write down unsold inventory.
From Heron Therapeutics's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Heron Therapeutics lost money in fiscal 2025: a net loss of $20 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments15885805947
Debt incl. finance leases14914915015033
Net debt (negative means net cash)−8646990−14
Net debt to EBITDA—————
Debt to equity1.9x11.0x——2.3x
Interest coverage−90.4x−70.6x−28.6x−1.9x−0.3x
Current ratio3.6x2.5x2.4x2.3x2.5x
Quick ratio2.9x1.8x1.8x1.7x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Heron Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Heron Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 93 of 94 of 9
Rule of 40−29.5%−3.2%−10.7%
Altman Z''−28.19−24.00−21.08
Accruals ratio−21.9%3.9%3.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assetsFailFailPass
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassPass
F-score3 of 93 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Heron Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Heron TherapeuticsFY257.4%−1.6%−18.0%−7.0%—4
LiquidiaFY251,031.2%−32.5%−25.3%———Compare
Syndax PharmaceuticalsFY25627.8%−158.4%−187.5%———Compare
Phathom PharmaceuticalsFY25216.9%−91.4%−95.4%——4Compare
KamadaFY2512.1%14.5%8.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue131781468986108127144155
Revenue growth—2,305.6%151.8%88.4%−39.3%−2.6%24.7%18.0%13.6%7.4%
Gross profit126508452405362106114
Research and development10313914016717413183391712
Operating income−171−195−184−211−228−218−175−111−12−2
Net income−173−198−179−205−227−221−182−111−14−20
Diluted EPS (US$)−4.56−3.65−2.44−2.50−2.50−2.24−1.67−0.80−0.09−0.12
Diluted shares (millions)385473829198109138152167
Cash flow
Cash from operations−134−170−192−125−185−203−147−59−22−28
Capital expenditure3397732220
Free cash flow−137−173−201−132−192−206−149−60−24−28
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation26303351504743331310
Balance sheet at fiscal year end
Cash and short-term investments5117233239120815885805947
Debt incl. finance leases—————14914915015033
Total assets68234462513354306251222233256
Total liabilities8910392109117228237256267242
Shareholders' equity−211313704042367814−34−3414
Margins and ratios
Gross margin97.3%85.1%64.5%57.8%59.2%46.7%49.0%48.8%73.2%73.3%
Operating margin−13,363.2%−632.4%−237.4%−144.3%−257.4%−252.3%−162.2%−87.1%−8.0%−1.6%
Net margin−13,537.4%−641.9%−230.8%−140.3%−256.4%−255.6%−169.1%−87.0%−9.4%−13.0%
Free cash flow margin−10,729.6%−561.8%−259.4%−90.2%−216.2%−239.0%−138.1%−47.5%−16.8%−18.0%
Rule of 40 (growth + FCF margin)—1,743.7%−107.6%−1.8%−255.5%−241.6%−113.4%−29.5%−3.2%−10.7%
Return on capital——————−187.7%−154.6%−19.8%−7.0%
Return on equity−357.5%−359.4%−71.3%−52.9%−71.0%−140.5%−399.4%———
Return on assets−168.7%−130.9%−51.4%−42.0%−52.5%−67.0%−65.4%−46.7%−6.0%−8.3%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Heron Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Heron Therapeutics.